Physician profile
Holly Doogs
NPI 1487433074
$908.07
in general payments reported to CMS, 2019-2025
18 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $442 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $148.68 | 2024-2025 | |
| Abbvie INC. | $105.65 | 2024-2025 | |
| Lilly USA, LLC | $76.56 | 2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $74.52 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $69.78 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $65.85 | 2024-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.95 | 2025 | Jardiance |
| Novo Nordisk INC | $58.28 | 2024-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.86 | 2024-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $30.42 | 2024 | Zoryve |
| Merck Sharp & Dohme LLC | $28.51 | 2024-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Lundbeck LLC | $27.74 | 2024 | Rexulti |
| Dexcom, INC. | $25.08 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $18.26 | 2024 | Voquezna |
| Organon LLC | $17.04 | 2025 | Nexplanon |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2024 | Trintellix |
| Pfizer INC. | $15.22 | 2025 | |
| Neurocrine Biosciences, INC. | $14.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Doogs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.